Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Benlysta | Belimumab | Systemic lupus erythematosus | Do not list | Complete | ||
Gelnique | Oxybutynin Chloride Gel | Overactive bladder | Do not list | Complete | ||
RAPAFLO | Silodosin | Benign prostatic hyperplasia | Do not list | Complete | ||
Saphris | Asenapine | Schizophrenia | Do not list | Complete | ||
Effient | Prasugrel | Acute coronary syndrome | Do not list | Complete | ||
Resotran | Prucalopride | Constipation, chronic | Do not list | Complete | ||
Mozobil | Plerixafor | Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma | Do not list | Complete | ||
Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Do not list | Complete | ||
Apprilon | Doxycycline monohydrate | Rosacea | Do not list | Complete | ||
Latuda | Lurasidone | Schizophrenia | Do not list | Complete |